ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals, Inc. (MM) (AMLN)

30.98
0.00
(0.00%)
Closed March 18 04:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
30.98
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
30.98
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

AMLN Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PIXYShiftPixy Inc
$ 6.80
(100.00%)
12.86M
STISolidion Technology Inc
$ 2.72
(56.32%)
90.62M
GOEVCanoo Inc
$ 2.9299
(51.03%)
108.38M
FRESFresh2 Group Ltd
$ 0.6903
(47.69%)
800.88k
AFIBAcutus Medical Inc
$ 0.2647
(35.81%)
6.92M
GMMGlobal Mofy Metaverse Ltd
$ 0.98
(-66.67%)
5.62M
SONDSonder Holdings Inc
$ 3.426
(-37.71%)
282.25k
WIMIWiMi Hologram Cloud Inc
$ 1.09
(-36.99%)
21.73M
WKSPWorksport Ltd
$ 0.47999
(-35.14%)
1.51M
MEDSTRxADE Health Inc
$ 19.60
(-31.94%)
165.37k
VERBVerb Technology Company Inc
$ 0.3589
(-18.84%)
248.26M
SQQQProShares UltraPro Short QQQ
$ 11.05
(-2.73%)
142.97M
GOEVCanoo Inc
$ 2.9299
(51.03%)
108.38M
TSLATesla Inc
$ 173.80
(6.25%)
108.21M
SOUNSoundHound AI Inc
$ 8.235
(-7.58%)
93.82M

AMLN Discussion

View Posts
DewDiligence DewDiligence 12 years ago
Curious to see how the AMLN buyout compares to other biotech buyouts? Please see the table in #msg-77140198.
👍️0
surf1944 surf1944 12 years ago
5:56AM Amylin Pharma to be acquired by Bristol-Myers Squibb (BMY) for $31.00/share or $5.3 bln; AstraZeneca (AZN) will make a payment to AMLN for $3.4 bln in cash; expected to be dilutive to BMY's FY2012 & 2013; slightly accretive by 2014 (AMLN) 28.22 +0.17 : BMY and AMLN announced that BMY will acquire AMLN for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of ~$5.3 bln. The total value of the transaction, including Amylin's net debt and a contractual payment obligation to Eli Lilly (LLY) together totaling about $1.7 bln, is ~$7 bln. The acquisition has been unanimously approved by the boards of directors of Bristol-Myers Squibb and Amylin. The board of directors of Amylin has unanimously recommended that Amylin's stockholders tender their shares into the tender offer.

Bristol-Myers Squibb and AstraZeneca (AZN) announced today that, following the completion of Bristol-Myers Squibb's acquisition of Amylin, the companies will enter into collaboration arrangements, based on the framework of the existing diabetes alliance, regarding the development and commercialization of Amylin's portfolio of products. Following completion of Bristol-Myers Squibb's acquisition of Amylin, AstraZeneca will make a payment to Amylin, as a wholly owned subsidiary of Bristol-Myers Squibb, in the amount of ~$3.4 bln in cash. Profits and losses arising from the collaboration will be shared equally. In addition, AstraZeneca has the option, exercisable at its sole discretion following the closing of the acquisition, to establish equal governance rights over key strategic and financial decisions regarding the collaboration, upon the payment to Bristol-Myers Squibb of an additional $135 mln. These collaboration arrangements have been approved by the boards of directors of Bristol-Myers Squibb and AstraZeneca.

Under the terms of the definitive merger agreement between Bristol-Myers Squibb and Amylin, Bristol-Myers Squibb will commence a cash tender offer to purchase all of the outstanding shares of Amylin's common stock for $31.00 per share. The merger agreement contains a provision under which Amylin has agreed not to solicit any competing offers for the company. Bristol-Myers Squibb will finance the acquisition from its existing cash resources and credit facilities. For Bristol-Myers Squibb, the transactions are expected to be dilutive to Non-GAAP earnings per share (EPS) in 2012 and 2013 by ~$0.03, becoming slightly accretive starting in 2014 with meaningful accretion expected in the later part of the decade. The estimated Non-GAAP EPS impact excludes amortization of acquired intangible assets, restructuring costs and other costs associated with the transactions.

AMLN stated "We are pleased to be able to strengthen the portfolio we have built to help patients with diabetes by building on the success Amylin has had with its GLP-1 franchise. The acquisition of Amylin by Bristol-Myers Squibb is also a unique way for Bristol-Myers Squibb and AstraZeneca to expand the alliance between the two companies, and it demonstrates Bristol-Myers Squibb's innovative and targeted approach to partnerships and business development."
👍️0
gixxer11 gixxer11 12 years ago
Bristol-Myers Squibb to Buy Amylin for $5.3 Billion



http://www.cnbc.com/id/48023979
👍️0
gixxer11 gixxer11 12 years ago
This will have heavy PM volume Monday :)
👍️0
surf1944 surf1944 12 years ago
12:59AM Amylin Pharma reports SYMLIN use helped patients with Type 2 or Type 1 Diabetes achieve more time in normal glucose range (AMLN) 27.50 : Co announces results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN injection treatment was used along with insulin. Two abstracts highlighting the analyses evaluated the proportion of readings from self-monitored seven-point glucose profiles that fell above, below or within glycemic targets based on guidelines set by the American Diabetes Association and American Association of Clinical Endocrinologists. In April of this year, the ADA and the European Association for the Study of Diabetes published a new Position Statement on the management of hyperglycemia in type 2 diabetes. The Position Statement included key clinical considerations for the use of SYMLIN, reaffirming its use in conjunction with mealtime insulin to decrease post-meal glucose excursions.
👍️0
north40000 north40000 12 years ago
7 companies interested enough to sign confidentiality pacts to explore potential buy-out of AMLN:

http://www.bloomberg.com/news/print/2012-05-15/amylin-said-to-attract-interest-from-pfizer-astrazeneca.html

I listened as best I could to ASM today[sound quality lousy]. No questions asked re buy-out potential---understandable,I guess.

AMLN + on heavier than usual volume, new 52 week high.
👍️0
surf1944 surf1944 12 years ago
7:13AM Amylin Pharma beats by $0.04, misses on revs (AMLN) 26.20 : Reports Q1 (Mar) loss of $0.23 per share, $0.04 better than the Capital IQ Consensus Estimate of ($0.27); revenues rose 0.7% year/year to $153.7 mln vs the $161.66 mln consensus. The increase in non-GAAP operating loss reflects investments to support the U.S. launch of BYDUREON (exenatide extended-release for injectable suspension)... While still early, we have seen a positive uptake of BYDUREON in the U.S. and Europe, and are pleased with the execution of our U.S. commercial launch... We have also made important progress against our other corporate priorities during the quarter. The recently expanded use of BYETTA with insulin glargine in the U.S. and Europe enables patients to achieve better glycemic control, without weight gain or an increased risk of hypoglycemia. In addition, we recently completed the Biologics License Application submission to the FDA for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in pediatric and adult patients with rare forms of lipodystrophy and are excited to advance this drug for patients who currently have such limited treatment options."
👍️0
Penny Roger$ Penny Roger$ 12 years ago
<<< $AMLN Links! >>> ~ MAC's Quick DD Links without the charts.




PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/AMLN


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/AMLN/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/AMLN/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/AMLN/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/AMLN/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/AMLN/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/AMLN/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/AMLN/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/AMLN/research


Google Finance Summary ~ http://www.google.com/finance?q=AMLN
Google Finance News ~ http://www.google.com/finance/company_news?q=AMLN
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=AMLN
Google Finance Financials ~ http://www.google.com/finance?q=AMLN&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=AMLN
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=AMLN&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=AMLN+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=AMLN+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=AMLN+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=AMLN
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=AMLN+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=AMLN+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/AMLN
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/AMLN
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=AMLN+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=AMLN+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=AMLN+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=AMLN+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=AMLN+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=AMLN+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=AMLN+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=AMLN+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=AMLN+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=AMLN+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=AMLN+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=AMLN&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=AMLN
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=AMLN
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=AMLN
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=AMLN
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=AMLN
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=AMLN&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=AMLN&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/AMLN?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/AMLN
Barchart Options Quotes ~ http://barchart.com/options/stocks/AMLN
Barchart Technical Chart ~ http://barchart.com/charts/stocks/AMLN&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/AMLN&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/AMLN
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=AMLN
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/AMLN
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/AMLN
Barchart News Headlines ~ http://barchart.com/news/stocks/AMLN
Barchart Profile ~ http://barchart.com/profile//AMLN
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=AMLN&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=AMLN&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=AMLN&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=AMLN&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/AMLN/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/AMLN/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/AMLN/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/AMLN/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/AMLN
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/AMLN/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/AMLN/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/AMLN/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/AMLN/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/AMLN/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/AMLN/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=AMLN&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=AMLN


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=AMLN


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=AMLN&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=AMLN
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=AMLN


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=AMLN&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=AMLN.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=AMLN®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/AMLN
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/AMLN/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/AMLN/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/AMLN/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=AMLN&selected=AMLN
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=AMLN&selected=AMLN
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/AMLN/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/AMLN/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/AMLN/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/AMLN/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/AMLN/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/AMLN/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/AMLN/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/AMLN/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/AMLN/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/AMLN/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/AMLN/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/AMLN/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/AMLN/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/AMLN/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=AMLN&selected=AMLN
NASDAQ Financials ~ http://www.nasdaq.com/symbol/AMLN/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/AMLN/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/AMLN/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/AMLN/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/AMLN/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/AMLN/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/AMLN/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/AMLN/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/AMLN.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/AMLN/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/AMLN/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/AMLN/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/AMLN/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/AMLN/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/AMLN/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=AMLN


YCharts ~ http://ycharts.com/companies/AMLN
YCharts Performance ~ http://ycharts.com/companies/AMLN/performance
YCharts Dashboard ~ http://ycharts.com/companies/AMLN/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=AMLN&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=AMLN&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=AMLN&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=AMLN


Zacks Quote ~ http://www.zacks.com/stock/quote/AMLN
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=AMLN
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=AMLN


Knobias ~ http://knobias.10kwizard.com/files.php?sym=AMLN


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=AMLN


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/AMLN/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=AMLN&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=AMLN®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=AMLN®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=AMLN®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=AMLN®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=AMLN®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=AMLN


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=AMLN


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=AMLN&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=AMLN&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=AMLN
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=AMLN&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=AMLN


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=AMLN


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=AMLN


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=AMLN

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=AMLN
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=AMLN

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=AMLN

Investorpoint ~ http://www.investorpoint.com/ enter "AMLN" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "AMLN" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=AMLN

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=AMLN

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=AMLN

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=AMLN

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=AMLN

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "AMLN" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=AMLN&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=AMLN
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=AMLN
Check those searches for recent AMLN mentions. If AMLN is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks
👍️0
Penny Roger$ Penny Roger$ 12 years ago
~ Thursday! $AMLN ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $AMLN ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=AMLN&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=AMLN&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=AMLN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=AMLN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=AMLN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=AMLN
Finviz: http://finviz.com/quote.ashx?t=AMLN
~ BusyStock: http://busystock.com/i.php?s=AMLN&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=AMLN >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
north40000 north40000 12 years ago
Icahn Issues Statement Regarding Amylin Pharmaceuticals



NEW YORK, April 25, 2012 /PRNewswire via COMTEX/ -- Carl C. Icahn today
announced that his affiliates had voluntarily dismissed their lawsuit against
Amylin Pharmaceuticals which had sought an extension of the deadline to nominate
directors at the 2012 annual meeting of shareholders. Mr. Icahn released the
following statement:

The decision to discontinue our lawsuit seeking to extend the director
nomination deadline was the result of discussions I had with Daniel Bradbury,
Amylin's chief executive officer, that we agreed would not be publicly
disclosed.

Mr. Icahn reiterated that he continues to strongly believe that the company
should be sold at this time.
👍️0
surf1944 surf1944 12 years ago
8:13AM Amylin Pharma: Carl Icahn confirms that he has issued an Open Letter to the Board of Directors of AMLN says 'believes any decision not to pursue a sale of the company at this time is a huge mistake' (AMLN) 24.11 : Icahn stated "As one of Amylin's largest shareholders, I find it reprehensible that the Board of Directors has still not acknowledged or denied the media reports regarding its rejection of a $22 per share takeover offer from Bristol-Myers Squibb (BMY). To this day, shareholders would not have known about this opportunity had the story not been leaked to the press. Still more egregious is the fact that, in the face of this reported $22 offer, the Board approved both (i) the public offering of 10% of the company at an assumed price of $15.62 per share on March 8th, without disclosing the Bristol-Myers offer in the registration statement that Amylin filed with the SEC..These actions make absolutely no sense to me in light of a Bristol-Myers bid and have served to substantially dilute shareholders who owned the stock when these actions were taken. I believe any decision not to pursue a sale of the company at this time is a huge mistake... I believe these nominees have been a positive force for change, but apparently their influence has not been enough to keep this Board from mishandling a Bristol-Myers proposal. In light of the failings mentioned above, it seems to me that the current Board is still dysfunctional and is not operating in a manner that enhances shareholder value... number of analysts in the investment community agree that the company faces daunting prospects in fully realizing the value of its products as an independent firm....Further, we delivered to Amylin on Tuesday a demand under Section 220 of the Delaware General Corporation Law for copies of Amylin's books and records, so that we may examine the circumstances surrounding the reported Bristol-Myers Squibb proposal and the stock offering and option grants following the date of the reported bid. These are matters that, in my opinion, shareholders are entitled to fully understand...In my view, a proxy contest at this time would be a costly distraction -- but I would not shy away from that possibility if I felt that the Board was not pursuing seriously the opportunity to sell the company.
👍️0
mlkrborn mlkrborn 12 years ago
History repeating? First down from 20 to 10 than sale @$22. Sme argue it is a rip off deal.

1. Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers
By John Carroll

Shares of Amylin Pharmaceuticals ($AMLN) rocketed up 45% this morning, fueled by a report by Bloomberg that the Bydureon developer had turned a cold shoulder to a $22 per share buyout offer from Bristol-Myers Squibb ($BMY), putting the value on this new potential pearl at $3.5 billion.

Amylin has had an eventful schedule over the past year. First it sued its longtime partner Eli Lilly ($LLY) after Lilly forged a marketing pact with rival Boehringer, then it executed an expensive divorce from the pharma giant. Soon after, the FDA delivered on a long-awaited approval for Bydureon, the once-weekly successor to the Byetta franchise. Now Meg Tirrell and Jeffrey McCracken, quoting sources close to the deal, report that Amylin rejected Bristol-Myers offer to pay a 43% premium to buy the company--a deal that would register as the largest in a string of 19 BMS acquisitions over the past five years.

As Bloomberg notes, Amylin has been seeing its revenue from Byetta shrink as Novo's ($NVO) Victoza muscled into its market share. And it's been looking for a global partner who can step into Eli Lilly's shoes outside the U.S. But none of that persuaded Amylin to warm up to Bristol-Myers' offer. BMS hasn't been back in touch since it was rejected by Amylin.

Amylin struck a $1.6 billion deal to end its relationship with Lilly. That included a $250 million upfront and a $1.2 billion share of the Bydureon revenue. The FDA's approval came soon after the two companies split up.

News of the $3.5 billion bid quickly seized the attention of Wall Street analysts, who began to debate just what Amylin is worth. Its value has a lot to do with its prospects for Bydureon, of course, and as Adam Feuerstein at TheStreet notes, if the board is turning down a $22 offer, they must have a strong belief that they can go on to register blockbuster sales. But if Bristol can't prevail, adds Feuerstein, the likes of Takeda, GlaxosmithKline and AstraZeneca just might step in.

- here's the story from Bloomberg
- here's the report from TheStreet
👍️0
surf1944 surf1944 12 years ago
Amilyn Soars on News of Spurned Bristol-Myers Bid

March 28, 2012, 10:01 A.M. ET


By Avi Salzman

Amilyn (AMLN) jumped 41% in early trading after a Bloomberg report said the drugmaker had rejected a $3.5 billion offer from Bristol-Myers Squibb (BMY) earlier this year. BMY proposed the deal in a letter to Amilyn, which makes diabetes drug Bydureon, but the board rejected it last month. It would have been worth $22 a share, which is 43% higher than Tuesday’s closing price, two sources told Bloomberg. Spokespeople for the companies declined to comment.

Bristol-Myers has relied on an acquisition strategy as some of its top drugs have lost patent protection.


Amylin Pharma AMLN Canaccord Genuity Sell $12(this anal-list looks like a monkey)
👍️0
surf1944 surf1944 12 years ago
Amylin Pharma AMLN Canaccord Genuity Sell $12
👍️0
surf1944 surf1944 12 years ago
9:03AM Amylin Pharma announces pricing of public offering of 13 mln shares of common stock; gross proceeds expected to be ~$203.1 mln (AMLN) 16.17 :
👍️0
surf1944 surf1944 12 years ago
7:55AM Amylin Pharma and Eli Lilly receive CHMP recommendation of approval for Byetta for use with basal insulin (AMLN) 18.07 : Amylin Pharmaceuticals and Eli Lilly (LLY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The CHMP's decision is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on CHMP recommendations within two to three months.
👍️0
WID WID 12 years ago
Musings on Amylin-inVentiv Deal

I revisited the Amylin-inVentiv Deal and thought that it might imply something:

Why AMLN does not create a sale force for Bydureon if the company want to make big $$$ on this blockbuster drug?

Why AMLN said in the agreement that it can notify inVentiv 60 days in advance to terminate the deal if necessary?

The deal at the time when the drug received FDA approval tell me that AMLN wants to sell the company to a big pharma that may have a well established diabetes sale force; thus AMLN does not have to layoff new hires for Bydureon commercial.

I think that AMLN will be taken over in the next 12 to 24 months.

What do you think?

All the best!
WID
👍️0
Pyckstocks Pyckstocks 12 years ago
~ AMLN~ Jefferies believes Amylin's 2012 guidance suggests upside to its Exenatide sales estimates. The firm upped its price target for shares post the company's Q4 results and keeps a Buy rating on the stock. Up $1.13
👍️0
equity8 equity8 12 years ago
"Alkermes earned $0.3 million in royalty revenues from type II diabetes treatment Bydureon" - Positive sign for Amylon EU revenues so far. http://www.zacks.com/stock/news/69054/Revenues+Skyrocket+at+Merged+Alkermes
👍️0
Docsfixinit Docsfixinit 12 years ago
Recent insider buys

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335505
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335506
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335499
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335501
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335497
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335498
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335494
👍️0
Docsfixinit Docsfixinit 12 years ago
Testing RESISTANCE !!!!!!!!!!!!
👍️0
shankapotamus shankapotamus 12 years ago
$AMLN chart opinion: http://blog.chartmystock.com/2012/01/29/amln-amylin-fda-approval-sends-price-up-in-ah-trading.aspx
👍️0
Docsfixinit Docsfixinit 12 years ago
$27.00 !!!!!!!!!!!
👍️0
Docsfixinit Docsfixinit 12 years ago
I have 4 family members with type 2 diabetes ,,,,you have no idea of hoe much this means to us !!!!!!!!!!!!!!
👍️0
Docsfixinit Docsfixinit 12 years ago



FDA Approves BYDUREON(TM) -- The First and Only Once-Weekly Treatment for Type 2 Diabetes

Last update: 1/27/2012 3:39:00 PM

Provides Glycemic Control in a Once-Weekly Dose

SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (AMLN) and Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON(TM) (exenatide extended-release for injectable suspension) - the first once-weekly treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple clinical settings. BYDUREON will be available in pharmacies nationwide in February.

To view the multimedia assets associated with this release, please visit:

"With BYDUREON, U.S. physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week," said John Buse, M.D., Ph.D., professor of medicine, director of the Diabetes Care Center and chief of the Division of Endocrinology at the University of North Carolina School of Medicine in Chapel Hill. "New treatment options are essential for the millions of adults with type 2 diabetes who continue to struggle to achieve optimal blood sugar control."

The approval of BYDUREON (pronounced by-DUR-ee-on) was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with BYDUREON resulted in improvements in glycemic control with just one dose per week. The approval was also based on clinical experience with BYETTA® (exenatide) injection, a twice-daily form of exenatide that has been available in the U.S. since June 2005 and is used in nearly 80 countries worldwide. BYDUREON uses Alkermes' proprietary technology for long-acting medications to provide a controlled release of exenatide.

"As the first and only once-weekly diabetes treatment, BYDUREON represents an important milestone in Amylin's promise to bring to market innovative therapies to help improve the lives of people with type 2 diabetes," said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. "BYDUREON builds upon the proven benefits of BYETTA, offering significant improvements in glycemic control in a single weekly dose."

In the DURATION-5 head-to-head clinical study, after 24 weeks of treatment, patients taking once-weekly BYDUREON experienced a statistically superior reduction in A1C of 1.6 percentage points from baseline, compared to a reduction of 0.9 percentage points for patients taking BYETTA. A1C is a measure of average blood sugar over three months. Both treatment groups achieved statistically significant weight loss by the end of the study, with an average loss of 5.1 pounds for patients taking BYDUREON and 3.0 pounds for patients taking BYETTA (weight loss was a secondary endpoint).The most frequently reported adverse event in both groups was nausea, reported less frequently by BYDUREON users (14 percent) than by BYETTA users (35 percent). Other common treatment-emergent adverse events in the BYDUREON group included diarrhea, upper respiratory tract infection and injection site nodules. There were no major hypoglycemic events.

BYDUREON has been approved with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of BYDUREON outweigh the risk of acute pancreatitis and the potential risk of medullary thyroid carcinoma. As part of the REMS, Amylin has established a communication plan for healthcare professionals to help minimize these risks. In addition, Amylin will fulfill a number of post-marketing requirements to further assess the impact of BYDUREON on medullary thyroid cancer and cardiovascular disease. More information will be available at .

BYDUREON is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous injection. In the DURATION clinical studies, the delivery system was well accepted by patients and physicians.
👍️0
Docsfixinit Docsfixinit 12 years ago
ALMN
Shares Outstanding 137,241,585 a/o Jul 25, 2008
Float Not Available
Authorized Shares Not Available
Par Value 0.001
👍️0
Docsfixinit Docsfixinit 12 years ago
http://finance.yahoo.com/news/FDA-Approves-BYDUREON-The-prnews-2702238983.html?x=0
👍️0
Docsfixinit Docsfixinit 12 years ago
BIG NEWS BYDUREON™ once a week diabetes drug
get it while it's still cheap
👍️0
oregon 1 oregon 1 12 years ago
APPROVED
👍️0
surf1944 surf1944 12 years ago
Amylin Pharmaceuticals, Inc. (AMLN)
Amylin is a biopharmaceutical company. The company currently focuses upon the discovery, development, and commercialization of drug candidates for the treatment of diabetes, and obesity.

FDA Pending News
On January 28, Amylin will attempt to begin the process in selling BYDUREON within the United States. The company has a pending FDA Prescription Drug User Fee Act (PDUFA) decision for the drug as a proposed treatment for type 2 diabetes. This is a resubission of a New Drug Application (NDA) for BYDUREON.

I believe the New Drug Application for BYDUREON will be approved based upon the January 9, 2012 Amylin Pharmaceuticals Inc at J.P. Morgan Global Healthcare Conference presentation.

Action
I am only trying to earn some option premium with a tight leash on maximum loss. I am long AMLN Feb 2012 10.000 calls (AMLN120218C00010000) and short the AMLN Feb 2012 9.000 call s (AMLN120218C00009000) for a 60 cent credit per contract. My maximum loss is 40 cents per contract.

http://seekingalpha.com/article/321945-fda-pending-catalysts-for-5-biotechs?source=yahoo
👍️0
surf1944 surf1944 12 years ago
Avg Vol (3 month)3: 1,961,420
Avg Vol (10 day)3: 1,609,350
Shares Outstanding5: 146.28M
Float: 131.26M
% Held by Insiders1: 0.36%
% Held by Institutions1: 93.00%
Shares Short (as of Nov 15, 2011)3: 9.12M
Short Ratio (as of Nov 15, 2011)3: 3.10
Short % of Float (as of Nov 15, 2011)3: 9.00%
Shares Short (prior month)3: 6.14M
👍️0
mlkrborn mlkrborn 12 years ago
AMLN $9.60 with "Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal
By John Carroll FierceBiotech
The decade-long union of Amylin ($AMLN) and Eli Lilly ($LLY) on the diabetes front ended in a blockbuster breakup today, with Amylin agreeing to pay Lilly $250 million upfront and up to $1.2 billion from the sales of exenatide products in exchange for full rights to the drug and its successors.

The divorce was presented today as an amicable ending to a long and fruitful partnership, but Amylin has been acting anything but amicably over the course of the year. The biotech filed suit against Eli Lilly earlier this year after the pharma giant joined forces with Boehringer Ingelheim, a rival in the diabetes field, on Trajenta. Today's agreement also ends the litigation.

Under the terms of the deal, Amylin will hand over a $1.2 billion secured note to Lilly, paying it off with the sales revenue from exenatide products. But if the FDA still hasn't approved the once-weekly injectable Bydureon--the successor to Byetta--by mid-2014, then the revenue sharing deal will terminate and Lilly's share of the sales revenue will shrink from 15% to 8%. FDA approval of a once-monthly version of the drug, now in mid-stage development, would trigger a $150 million milestone payment. Transitioning worldwide commercialization and development of new exenatide products starts in the U.S. at the end of this month then rolls around the globe by the end of 2013.

"Lilly remains confident that the resubmission package for Bydureon has addressed the requirements outlined by the FDA and looks forward to Amylin achieving the alliance's long-held goal of making Bydureon available to patients in the U.S.," said Enrique Conterno, president of Lilly Diabetes. "Looking forward, Lilly Diabetes remains committed to providing a comprehensive portfolio of diabetes treatment options for patients through our currently marketed products and robust clinical pipeline."

Alkermes, which has a royalty stake in the success of Bydureon, will evidently stay with Amylin now that the two big partners have severed their union."
source: FierceBiotech

👍️0
surf1944 surf1944 13 years ago
7:10AM Amylin Pharma, Eli Lilly (LLY), and Alkermes (ALKS) announced positive analyses from the DURATION-3 and -4 trials (AMLN) 10.63 : Cos announced that patients treated with the investigational medication BYDUREON experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients receiving BYDUREON for the treatment of type 2 diabetes experienced improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels.
👍️0
surf1944 surf1944 13 years ago
1. AMYLIN PHARMACEUTICALS INC (AMLN): AMLN recently traded at $10.11 and lost 49.2% during the past 12 months. The stock has a market cap of $1.5 billion. Icahn had $164 million invested in AMLN shares. Steven Cohen’s Sac Capital Advisors and Christopher Medlock James’ Partner Fund Management also have relatively small positions in AMLN.

http://seekingalpha.com/article/287348-carl-icahn-s-long-term-holdings?source=yahoo
👍️0
surf1944 surf1944 13 years ago
7:39AM Amylin Pharma misses by $0.04, reports revs in-line (AMLN) 13.30 : Reports Q2 (Jun) loss of $0.21 per share, excluding items, $0.04 worse than the Capital IQ Consensus Estimate of ($0.17); revenues rose 2.1% year/year to $158.1 mln vs the $157.1 mln consensus.
👍️0
surf1944 surf1944 13 years ago
Amylin, Alkermes say diabetes drug safe for heart
Amylin and partners say weekly diabetes injection does not affect heart activity

On Thursday July 7, 2011, 6:55 pm EDT

WASHINGTON (AP) -- Shares of Amylin and Alkermes Inc. climbed Thursday after the companies said their once-per-week diabetes medication appears safe for the heart, addressing concerns that delayed its federal review last year.

The drug, Bydureon, is designed to be a next-generation version of the twice-daily injection Byetta, which is currently marketed by Amylin and Eli Lilly & Co. Inc. Alkermes, based in Waltham, Mass., created the technology that gradually releases the drug over the course of a week.

The Food and Drug Administration declined approval for Bydureon in October, saying more information on its effect on the heart was needed.

The companies said a 75-patient study of Bydureon showed it did not interfere with the electrical activity of the heart even at high doses, a key safety measure in drug trials.

"We are confident in these results and will continue to work toward making Bydureon available to patients in the U.S. as soon as possible," said Christian Weyer, senior vice president at Amylin Pharmaceuticals.

Bydureon is part of a new wave of diabetes treatments designed to treat the rising epidemic of the disease in the U.S. However, the FDA has raised safety standards for such treatments after GlaxoSmithKline's blockbuster diabetes pill Avandia was linked to heart attack risks.

New drugs that have already reached the market include Merck & Co.'s Januvia and Bristol-Myers Squibb Co. and AstraZeneca's Onglyza. Those drugs are technically in a different class from Bydureon but work with the same goal of controlling blood sugar levels.

Regulators for the European Union approved Bydureon last month.

Lilly is based in Indianapolis, and Amylin is headquartered in San Diego.

Shares of Amylin Pharmaceuticals Inc. rose $1.44, or 10.5 percent, to $15.15 in afterhours trading. Alkermes tacked on $1.17, or 6 percent, to $20.40. Lilly was unchanged.
👍️0
surf1944 surf1944 13 years ago
http://www.secform4.com/insider-trading/881464.htm
👍️0
surf1944 surf1944 13 years ago
Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
Majority of Patients Reached the ADA Treatment Target for Glycemic Control

Follow these stocks
Press Release Source: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc. On Friday June 24, 2011, 5:00 pm EDT

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN - News), Eli Lilly and Company (NYSE:LLY - News) and Alkermes, Inc. (Nasdaq:ALKS - News) today announced additional results from a phase 2 study of an investigational, once-monthly injectable suspension formulation of exenatide which showed substantial improvements in glycemic control, including reductions in A1C and fasting plasma glucose, with modest weight loss. These findings will be presented in a late breaking poster session at the 71st Scientific Sessions of the American Diabetes Association on Sunday, June 26 from 12-2 p.m. PDT.

The 121-patient study assessed the efficacy, safety and tolerability of three different doses (5 mg, 8 mg and 11 mg) of exenatide once monthly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. After 20 weeks of treatment (total of five injections), patients receiving exenatide once monthly experienced average improvements in A1C (a measure of average blood sugar over three months) from baseline of 1.3 percentage points for the 5 mg and 8 mg doses and 1.5 percentage points for the 11 mg dose. In addition, 50 percent of those treated with the 5 mg dose, 57 percent treated with the 8 mg dose and 70 percent treated with the 11 mg dose achieved an A1C of less than 7 percent, the ADA-recommended target for good glucose control. Patients also lost a modest amount of weight (0.9 pounds with the 8 mg dose and 2.4 pounds with the 5 mg and 11 mg doses), although exenatide once monthly is not being studied as a weight-loss product. Fasting plasma glucose was improved with all doses, with reductions of 25 mg/dL with the 5 mg dose, 30 mg/dL with the 8 mg dose and 49 mg/dL with the 11 mg dose. The mean pharmacokinetic profile showed all three exenatide once monthly doses resulted in steady-state exenatide plasma levels within the known therapeutic range.

As a reference arm, the study also included patients receiving BYDUREON™ (exenatide extended-release for injectable suspension), another investigational form of exenatide that is dosed once-weekly. Results for A1C, fasting glucose and weight in the exenatide once monthly treatment arms were generally comparable to those seen in the BYDUREON reference arm. Patients receiving BYDUREON experienced reductions in A1C (1.5 percentage points), fasting plasma glucose (34 mg/dL) and weight (3.1 pounds) compared to baseline.

"Our exenatide suspension program builds upon our extensive experience and knowledge gained throughout the development of BYETTA and BYDUREON, and suggests promise in harnessing the therapeutic potential of continuous GLP-1 agonism in a monthly dose," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "We are committed to expanding the treatment options available to patients living with type 2 diabetes through the continued investigation of additional formulations of exenatide."

More than 90 percent of patients completed the study. The most common adverse events within the exenatide once monthly treatment groups were headache (17-27 percent) and nausea (17-23 percent). Headache (30 percent) and diarrhea (27 percent) were most common among the BYDUREON group. No major or minor hypoglycemia was reported in the study. The duration of adverse events was generally similar between treatment groups.

Exenatide once monthly is an investigational, extended-release formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which is given twice daily. Exenatide once monthly is based on the same microsphere technology used in BYDUREON. BYDUREON is the proposed brand name for exenatide extended-release for injectable suspension, an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON received marketing authorization in the European Union earlier this month.

Study Design

This phase 2, randomized, open-label, dose-ranging study included 121 adults with type 2 diabetes (baseline A1C: 8.6 percent for BYDUREON and 8.4-8.5 percent for exenatide once monthly) who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos® (pioglitazone) or both. Subjects were randomized to receive either 2 mg weekly subcutaneous injections of BYDUREON or subcutaneous injections of exenatide once monthly at a low (5 mg), medium (8 mg) or high (11 mg) dose administered once every four weeks for 20 weeks.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(i)(ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs more than $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi)(vii)
👍️0
surf1944 surf1944 13 years ago
The Diabetes Trade: Why We Like Amylin

In my recent manifesto about diabetes, I briefly touched upon Amylin Pharmaceuticals (AMLN). As most readers are aware, Amylin focuses the majority of its R&D on drugs for type 2 diabetes and obesity.

We believe that Amylin's pipeline could fit in with well with that of several large pharmaceuticals. Many drug companies have been cutting back on R&D and intend to make further cuts in the upcoming years. It all boils down to a risk-reward dynamic. Big pharma may determine that it is more cost effective to look elsewhere for future products rather than to try to keep developing them on their own. Amylin’s current drugs are Symlin, used to treat both type 1 and type 2 diabetes, and Byetta, which treats just type 2 diabetes.

Byetta is Amylin's flagship drug, and comprises more than 80% of its revenues. The only problem is that Byetta is expected to come off patent in 2013. Amylin is currently developing other versions of Byetta. These phase II and phase III trials are determining if the efficacy of the drug can be used in alternative delivery and dosing methods, respectively. The revamped Byetta line in the later trial stages should most likely win approval based on the fact that they are reformulated versions of existing drugs.

There are several large pharmas that may have an interest in Amylin. We believe that Eli Lilly (LLY), a current partner, is the most likely winner. Of the other companies interested, including Merck (MRK) and Pfizer (PFE), Pfizer is perhaps the more likely candidate, having recently been losing market share to two of the largest diabetes drug manufacturers, Sanofi-Aventis (SNY) and Novo Nordisk (NVO). Amylin's pipeline could give Pfizer much need market share in the diabetes sector of the industry. Pfizer has only one type 2 diabetes drug in phase II trials; the other nine are all in phase I.

Amylin’s market cap is around $2 billion and the stock trades for around $13 dollars a share. Revenues have declined 12% year over year, as other diabetes drugs have eaten into Amylin’s market share. Any type deal that involves a small biotech-pharma is always risky, and trials may have to progress further before another company is comfortable enough to pull the trigger. Carl Icahn's 10% stake in Amylin is another question mark that merits consideration. As an activist shareholder, his letter to the board was not unexpected to say the least. If Mr. Icahn has his way, he will either get the new management that he is seeking or will convince the powers that be to sell some or all of the company, thus unlocking Amylin's value.

There is little clarity on how this will ultimately shake out. Either way, Amylin will undergo a changing environment. We feel that between its precision execution on cost-cutting and the likelihood of approval on its new delivery methods for Byetta, Amylin could see $20 - $22 representing full value for the stock - a far cry from its all time high of $53.25 in August of 2007, but still a nice return from here.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

http://seekingalpha.com/article/277351-the-diabetes-trade-why-we-like-amylin?source=yahoo
👍️0
surf1944 surf1944 13 years ago
http://www.nasdaq.com/asp/holdings.asp?symbol=AMLN&selected=AMLN&FormType=Institutional
👍️0
trade2much trade2much 13 years ago
Bob... this could be a good play for a while the "expert committee" in the EU recommended approval for this type2 diabetes drug. The regulatory committee has a habit of going with the committee's recommendations and my mid to end Jun we should get an approval imo. If so this should be a big deal for AMLN. Type 2 diabetes patients now have to do injections daily into their stomach etc, this is supposed to make that now weekly if approved. I can't think too many wouldn't opt for this as a result.
👍️0
BobStockguy BobStockguy 13 years ago
Picked up this from a news blast this morning
Stock Pop Alert !News (AMLN) on the run. Bullish
(SHAR) alert trading at 15 day high

AMLN NEWS LINK : http://www.alphatrade.com/news/stories/AM/2011-04-15/BIZ/201104150725BIZWIRE_USPR_____BW5427.html
👍️0
surf1944 surf1944 13 years ago
8:02AM Amylin Pharma and Takeda voluntarily suspend clinical activities in obesity trial (AMLN) 11.03 : Co and Takeda Pharmaceutical announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.
👍️0
surf1944 surf1944 13 years ago
8:01AM Amylin Pharma, Eli Lilly (LLY) and Alkermes (ALKS) announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes (AMLN) 11.34 : AMLN, LLY, and ALKS announce positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes. After 20 weeks of treatment (five injections), patients randomized to the exenatide once monthly treatment arms experienced average reductions in A1C ranging between 1.3-1.5 percentage points from baseline. In the once-weekly BYDUREON treatment arm, the reduction was 1.5 percentage points. A1C is a measure of average blood sugar over three months. More than 90% of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly BYDUREON group. No major or minor hypoglycemia was reported in the study.
👍️0
Blutribe Blutribe 13 years ago
Bloomberg article...possible buyout??....Lilly's Diabetes Setbacks May Spur Shopping Spree Beyond Amylin
By Catherine Larkin - Oct 22, 2010 4:18 PM ET



Eli Lilly CEO John Lechleiter

John Lechleiter, chairman, president, and chief executive officer of Eli Lilly & Co. Photographer: Jeff Kowalsky/Bloomberg

Eli Lilly & Co., under pressure to gain new products after setbacks this week with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc. or covet companies with more approved products.

With Amylin, Lilly would gain full control of the diabetes drug Byetta and a longer-acting version called Bydureon delayed Oct. 19 by U.S. regulators, said Seamus Fernandez, a Leerink Swann & Co. analyst. Lilly might try to acquire Cephalon Inc. or Endo Pharmaceuticals Inc. to expand its painkiller business, said Bill Tanner, an analyst at Lazard Capital Markets.

By 2013, Lilly loses patents on medicines responsible for almost half its revenue. The Bydureon rejection, which stalled a new revenue source for at least two years, was compounded Oct. 20 when the company halted tests on a second experimental diabetes medicine because it wasn’t effective. Lilly Chief Executive Officer John Lechleiter yesterday ruled out “large- scale combinations” while expressing interest in smaller deals.

“An outright acquisition of Amylin certainly could make sense” if Lilly thinks Bydureon will be approved, Fernandez said in a telephone interview from Boston. Amylin, based in San Diego, lost half its market value on Oct. 20 after the Food and Drug Administration requested a study of Bydureon’s effect on heart rhythm.

Amylin fell 18 cents, or 1.6 percent, to $11.30 at 4 p.m. in Nasdaq Stock Market composite trading, after a 46 percent plunge on Oct. 20. Indianapolis-based Lilly fell 10 cents to $35.40 in New York Stock Exchange composite trading.

40 Percent Premium

The average premium paid in the last 12 months for acquisitions of U.S. medical and biotechnology companies was 40 percent, according to data compiled by Bloomberg. That suggests Amylin may have cost $2.3 billion yesterday, excluding debt, compared with $3.4 billion before shares plunged this week. Lilly had $5.16 billion in cash to make deals as of June.

Other diabetes-drug developers led by Pfizer Inc. and Sanofi-Aventis SA, may also pursue Amylin at its bargain price, Fernandez said. Ray Kerins, a spokesman for New York-based Pfizer, the world’s largest drugmaker, didn’t return calls for comment. Jean-Marc Podvin, a spokesman for Paris-based Sanofi, said he doesn’t comment on market rumors.

“We are very satisfied with our current relationship with Amylin and their management team,” Mark Taylor, a Lilly spokesman, said yesterday in an e-mail.

Shareholder Value

“Executing our current business strategy, including working with the FDA to bring Bydureon to patients as quickly as possible, is the best way to increase value for our shareholders,” said Alice Izzo, an Amylin spokeswoman, in an e- mail.

While there is risk Amylin may be the target of an opportunistic acquirer, it’s not likely the company would solicit offers, said Howard E. Greene Jr., a co-founder who resigned from the board last year, in an Oct. 20 telephone interview.

“Whenever the stock gets whacked, you have to assume that some people are going to sharpen their pencils,” Greene said. “Two things happen: shareholders are mad, and companies with bundles of cash are standing on the sidelines, waiting for an opportunity.”

Lilly paid an undisclosed amount in July to buy closely held Alnara Pharmaceuticals Inc., the maker of a drug for pancreatic insufficiency. Lilly also said in March that it would pay an undisclosed amount to buy European rights to certain animal drugs from Pfizer and a manufacturing plant in Ireland.

‘Fundamental Strategy’

“Our fundamental strategy remains intact,” Lechleiter said during a conference call yesterday. “We’re not interested in large-scale combinations. I think there are many other opportunities that I think we could consider along the lines of several that we have done this year.”

Lechleiter’s plan to stick to small purchases or licensing deals won’t give investors much confidence, said Barbara Ryan, an analyst with Deutsche Bank in New York, in a telephone interview.

“A lot of those companies will just be adding to the pipeline and they’re not going to be something that the market will accrue much value to on Lilly,” Ryan said.

United Therapeutics Corp. may also be a good fit because Lilly has an 11 percent stake and the two companies are partnered on Adcirca, a lung treatment made from the ingredient in Lilly’s impotence pill Cialis, according to Fernandez. Forest Laboratories Inc. would be another option to complement Lilly’s research in antidepressants and arthritis medicines, he said.

‘Takeover Target’

“It is not our expectation that we’re an imminent takeover target for Eli Lilly,” said Andrew Fisher, a spokesman for Silver Spring, Maryland-based United Therapeutics, in a telephone interview. The 2008 Cialis marketing agreement prevents Lilly from attempting a takeover before 2014, he said.

Cephalon doesn’t comment on rumor or speculation, said Candace Steele, a spokeswoman for the Frazer, Pennsylvania-based company. Kevin Wiggins, of Chadds Ford, Pennsylvania-based Endo, also declined to comment as a matter of company policy. Frank Murdolo, a spokesman for New York-based Forest, didn’t return a telephone message for comment.

The patent expires next year for Lilly’s top-selling antipsychotic Zyprexa, which brought in $4.92 billion last year. Generic copies of the antidepressant Cymbalta and insulin product Humalog may be introduced in 2013. Had Bydureon been approved this week, it could have generated sales of $420 million next year, said Phil Nadeau, an analyst with Cowen & Co. in New York.

Tanner, of Lazard, estimates a fair price for Amylin would be as much as $15 a share, or about $2.16 billion based on 143.7 million shares outstanding as of June. He said Bydureon sales will be limited because there are at least six competing diabetes drugs in development -- including one from Lilly -- as well as one approved product, Novo Nordisk S/A’s Victoza.

“The chances that this drug makes it to market are probably pretty high, but you’re looking at almost two years from now,” Tanner said. “If it didn’t make it, then somebody would have massively overpaid for Amylin.”

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.
👍️0
mlkrborn mlkrborn 13 years ago
SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., Oct 19, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide extended-release for injectable suspension).

In the complete response letter the FDA requested a thorough QT (tQT) study with exposures of exenatide higher than typical therapeutic levels of BYDUREON. The tQT protocol will be agreed to by the FDA prior to study initiation. Additionally, the FDA has now requested the results of the DURATION-5 study to evaluate the efficacy, and the labeling of the safety and effectiveness, of the commercial formulation of BYDUREON. This letter did not cite any manufacturing processes referenced in the FDA's March 15 complete response letter. REMS and product labeling discussions will continue following submission of the additional data.

The companies' goal is to submit their reply to the complete response letter by the end of 2011, pending discussions with the FDA. Based on the requirements for additional data, this will likely be considered a Class 2 resubmission requiring a six-month review.

"We are committed to working closely with the FDA to resolve the issues raised in the complete response letter so that BYDUREON can be approved, and we can make this important treatment available to patients with type 2 diabetes as quickly as possible," said Orville G. Kolterman, M.D., senior vice president, chief medical officer, Amylin Pharmaceuticals. "We remain confident in BYDUREON based on the extensive exenatide database, including more than seven years of clinical experience with BYETTA, the twice-daily form of exenatide that is available in more than 60 countries worldwide."

BYDUREON (pronounced by-DUR-ee-on) is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA(R) (exenatide) injection. BYETTA has been available in the U.S. since June 2005 and is used in more than 60 countries worldwide to improve glycemic control in adults with type 2 diabetes. BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications.

The NDA for BYDUREON was submitted in May 2009 and is based on data that include the DURATION-1 head-to-head clinical study, safety data from DURATION-2 and more than seven years of clinical experience with BYETTA. The agency issued a complete response letter to the companies in March 2010 and in May 2010 classified the companies' first complete response as a Class 2 resubmission with a PDUFA action date of October 22, 2010.

Amylin to Host Investor Conference Call

Amylin will host a conference call to discuss the complete response letter for BYDUREON at 4 p.m. PT on Oct. 19. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will lead the call.

The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to approximately 15 minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (800) 857-5738 begin_of_the_skype_highlighting (800) 857-5738 end_of_the_skype_highlighting (U.S./Canada) or (415) 228-4970 begin_of_the_skype_highlighting (415) 228-4970 end_of_the_skype_highlighting (international), conference access code 7487145. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (866) 375-1047 begin_of_the_skype_highlighting (866) 375-1047 end_of_the_skype_highlighting (U.S./Canada) or (203) 369-0288 begin_of_the_skype_highlighting (203) 369-0288 end_of_the_skype_highlighting (international).
👍️0
mlkrborn mlkrborn 13 years ago
Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
Date : 10/19/2010 @ 7:06PM
Source : PR Newswire
Stock : Amylin Pharmaceuticals (MM) (AMLN)
Quote : 10.17 -10.32 (-50.37%) @ 7:22AM


Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
Amylin Pharmaceuticals (MM) (NASDAQ:AMLN)
Intraday Stock Chart

Today : Wednesday 20 October 2010
Click Here for more Amylin Pharmaceuticals (MM) Charts.

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that unaudited net product sales for the quarter ended September 30, 2010 were $154.0 million. Unaudited net product sales for the quarter include $132.4 million for BYETTA® (exanatide) injection and $21.6 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $192.9 million consisting of $171.1 million for BYETTA and $21.8 million for SYMLIN for the same period in 2009. Amylin plans to report full financial results for the quarter and nine months ended September 30, 2010 within the next few weeks pending its assessment of the potential financial impact of the U.S. Food and Drug Administration complete response letter regarding BYDUREON™ (exenatide extended-release for injectable suspension).

Amylin also announced that the previously announced quarterly update conference call, originally scheduled for Wednesday, October 20, 2010 at 5:00 p.m. ET/2:00 p.m. PT., has been canceled.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.
👍️0
mlkrborn mlkrborn 13 years ago
AMLN: Down $10 to $10.
By Val Brickates Kennedy

NVO AMLN ALKS LLY

BOSTON (MarketWatch) -- Shares of Danish drug maker Novo Nordisk A/S /quotes/comstock/13*!nvo/quotes/nls/nvo (NVO 100.51, +9.52, +10.46%) jumped 10% in premarket trading Wednesday, the day after U.S. regulators declined to approve a hotly-anticipated diabetes medication called Bydureon that posed a competitive threat to Novo's diabetes drug franchise. Novo shares had been trading substantially lower recently in anticipation of a U.S. approval for the product. Bydureon was co-developed by Amylin Pharmaceuticals /quotes/comstock/15*!amln/quotes/nls/amln (AMLN 10.12, -10.37, -50.61%) , Alkermes Inc. /quotes/comstock/15*!alks/quotes/nls/alks (ALKS 10.35, -4.15, -28.62%) and Eli Lilly & Co. /quotes/comstock/13*!lly/quotes/nls/lly (LLY 35.62, -1.83, -4.89%) .

👍️0
Volume Volume 13 years ago
Deutsche Bank Maintains a 'Buy' on Amylin Pharmaceuticals #AMLN#; Thinking Long-Term: Bydureon a Likely Blockbuster


September 24, 2010 8:06 AM EDT

Deutsche Bank maintains a 'Buy' on Amylin Pharmaceuticals (Nasdaq: AMLN), PT $27.

Deutsche analyst says, "Amylin is awaiting approval of its long-acting diabetes drug, Bydureon, which is a GLP-1 agonist. This class of drugs is used after oral therapy before insulin. Street controversy has focused not on IF Bydureon will be approved (Oct 22 is FDA PDUFA date), but how BIG peak sales will be. Our analysis suggests peak sales of Bydureon of $1.4B in '14 and $3B by '20 in the U.S. alone. We rate the stock a Buy because we believe Bydureon sales will be greater than street expectations."

"NY Times reported a potential sale of Amylin in ’09. We view Amylin as a possible acquisition candidate for a large pharma company with a diabetes sales force. Acquirer could extract significant SG&A and R&D synergies. Our M&A analysis indicates Lilly (NYSE: ELY) and Takeda make most sense with M&A value at $43-$44/share."

To see all the upgrades/downgrades on shares of AMLN, visit our Analyst Ratings page.

The 52-wk trading range is $11.01 - 24.21.
👍️0
Volume Volume 13 years ago
Rumor: Amylin spikes up on renewed takeover speculation

On The Fly: Rumor Buzz
Market speculation today includes Amylin Pharmaceuticals (AMLN) which is said to be holding talks with Eli Lilly & Co. (LLY) for as much as $32 per share...Brocade Communications Systems (BRCD), up nearly 8%, is reportedly in talks with IBM (IBM) for $7.50 per share...DISH Network Corp. (DISH) is rumored to be acquiring TiVo (TIVO)...Banco Santander, S.A. (STD) is speculated again to be considering a bid for M&T Bank Corp. (MTB)...Semiconductor company Cree (CREE) is again the subject of takeover speculation. Last week Siemens (SI) was rumored to be considering a bid. :theflyonthewall

Amylin October volatility at 48, November elevated at 80 into PDUFA
Amylin is recently up 2c to $20.92 on renewed takeover chatter. PDUFA date for Bydureon is October 22. October option implied volatility is at 48, November is at 80, January is at 64 versus its 26-week average of 72. About 4,661 calls (616 puts) traded in AMLN with short term speculation focused on October 22 and October 24 calls according to Track Data, suggesting traders are expecting larger price movement. :theflyonthewall.com
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com